Een onderzoek naar sequentiële therapie met Daplusiran/Tomligisiran (DAP/TOM), gevolgd door Bepirovirsen bij deelnemers die leven met chronische hepatitis B (CHB) (B-UNITED)
Een fase 2b, multicenter, gerandomiseerde, gedeeltelijk placebogecontroleerde, dubbelblinde studie om de veiligheid en werkzaamheid te onderzoeken van sequentiële therapie met Daplusiran/Tomligisiran gevolgd door Bepirovirsen bij deelnemers met chronisch hepatitis B-virus op achtergrond-nucleos(t)ide-analoog Therapie (B-United)
The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen. The study will also include an optional long-term follow-up (LTFU) extension stage for eligible participants.
Studie Overzicht
Toestand
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Westmead, New South Wales, Australië, 2145
- GSK Investigational Site
-
-
Victoria
-
Fitzroy, Victoria, Australië, 3065
- GSK Investigational Site
-
-
-
-
-
Brussels, België, 1000
- GSK Investigational Site
-
Edegem, België, 2650
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, België, 9000
- GSK Investigational Site
-
-
-
-
-
Aracaju, Brazilië, 49060-010
- GSK Investigational Site
-
Curitiba, Brazilië, 80810-050
- GSK Investigational Site
-
Manaus, Brazilië, 69040-000
- GSK Investigational Site
-
São Paulo, Brazilië, 05403-000
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- GSK Investigational Site
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H8L6
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 2C4
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- GSK Investigational Site
-
-
-
-
-
Beijing, China, 100050
- GSK Investigational Site
-
Chengdu, China, 610072
- GSK Investigational Site
-
Guangzhou, China, 510630
- GSK Investigational Site
-
Shanghai, China, 200040
- GSK Investigational Site
-
-
-
-
-
Berlin, Duitsland, 10787
- GSK Investigational Site
-
Berlin, Duitsland, 10439
- GSK Investigational Site
-
Münster, Duitsland, 48149
- GSK Investigational Site
-
-
Lower Saxony
-
Hanover, Lower Saxony, Duitsland, 30625
- GSK Investigational Site
-
-
-
-
-
Clichy, Frankrijk, 92118
- GSK Investigational Site
-
Créteil, Frankrijk, 94010
- GSK Investigational Site
-
Limoges, Frankrijk, 87042
- GSK Investigational Site
-
Lyon, Frankrijk, 69004
- GSK Investigational Site
-
Marseille, Frankrijk, 13008
- GSK Investigational Site
-
-
-
-
-
Athens, Griekenland, 10676
- GSK Investigational Site
-
Athens, Griekenland, 11527
- GSK Investigational Site
-
-
-
-
-
Pokfulam, Hongkong
- GSK Investigational Site
-
Shatin, Hongkong
- GSK Investigational Site
-
-
-
-
-
Bergamo, Italië, 24127
- GSK Investigational Site
-
Florence, Italië, 50134
- GSK Investigational Site
-
Milan, Italië
- GSK Investigational Site
-
Naples, Italië, 80131
- GSK Investigational Site
-
Padova, Italië, 35131
- GSK Investigational Site
-
Pisa, Italië, 56124
- GSK Investigational Site
-
Roma, Italië, 00161
- GSK Investigational Site
-
-
-
-
-
Chiba, Japan, 270-1694
- GSK Investigational Site
-
Hokkaido, Japan, 006-8555
- GSK Investigational Site
-
Hokkaido, Japan, 053-8506
- GSK Investigational Site
-
Hyōgo, Japan, 660-8550
- GSK Investigational Site
-
Kagawa, Japan, 761-0793
- GSK Investigational Site
-
Kagawa, Japan, 760-8557
- GSK Investigational Site
-
Kumamoto, Japan, 860-8556
- GSK Investigational Site
-
Kumamoto, Japan, 862-8655
- GSK Investigational Site
-
Osaka, Japan, 540-0006
- GSK Investigational Site
-
Osaka, Japan, 565-0871
- GSK Investigational Site
-
Tokyo, Japan, 180-8610
- GSK Investigational Site
-
Yamanashi, Japan, 409-3898
- GSK Investigational Site
-
-
-
-
-
Auckland, Nieuw-Zeeland, 2025
- GSK Investigational Site
-
Auckland, Nieuw-Zeeland, 1023
- GSK Investigational Site
-
-
-
-
-
Singapore, Singapore, 119074
- GSK Investigational Site
-
Singapore, Singapore, 169608
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanje, 08036
- GSK Investigational Site
-
Barcelona, Spanje, 08035
- GSK Investigational Site
-
León, Spanje, 24080
- GSK Investigational Site
-
Madrid, Spanje, 28041
- GSK Investigational Site
-
Salamanca, Spanje, 37007
- GSK Investigational Site
-
Santander, Spanje, 39008
- GSK Investigational Site
-
Valencia, Spanje, 46026
- GSK Investigational Site
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- GSK Investigational Site
-
Kaohsiung City, Taiwan, 824
- GSK Investigational Site
-
Taichung, Taiwan, 404
- GSK Investigational Site
-
Tau-Yuan, Taiwan, 333
- GSK Investigational Site
-
-
-
-
-
London, Verenigd Koninkrijk, SE5 9RS
- GSK Investigational Site
-
London, Verenigd Koninkrijk, SW17 0QT
- GSK Investigational Site
-
London, Verenigd Koninkrijk, E1 8PR
- GSK Investigational Site
-
Middlesbrough, Verenigd Koninkrijk, TS4 3BW
- GSK Investigational Site
-
-
-
-
California
-
San Francisco, California, Verenigde Staten, 94115
- GSK Investigational Site
-
San Jose, California, Verenigde Staten, 95116
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55415
- GSK Investigational Site
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- GSK Investigational Site
-
-
-
-
-
Ansan, Zuid -Korea, 15355
- GSK Investigational Site
-
Busan, Zuid -Korea, 47392
- GSK Investigational Site
-
Pusan, Zuid -Korea, 49241
- GSK Investigational Site
-
Seoul, Zuid -Korea, 138-736
- GSK Investigational Site
-
Seoul, Zuid -Korea, 07061
- GSK Investigational Site
-
-
-
-
-
Ekurhuleni, Zuid-Afrika, 1459
- GSK Investigational Site
-
Johannesburg, Zuid-Afrika, 2193
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age: At least 18 years of age at the time of signing the informed consent
- Documented chronic HBV infection greater than or equal to (>=) 6 months prior to Screening AND currently receiving stable NA therapy defined as receiving an NA regimen form at least 6 months prior to Screening and with no planned changes to their stable regimen over the duration of the study.
- Plasma or serum HBsAg concentration greater than (>) 100 international units per milliliter (IU/mL)
- Plasma or serum HBV DNA concentration must be adequately suppressed, defined as plasma or serum HBV DNA less than (<) 90 IU/mL
- Alanine aminotransferase less than or equal to (<=) 2* upper limit of normal (ULN)
- Participants who are willing and able to cease their NA treatment in accordance with the protocol.
- Male and Female
Exclusion Criteria:
- Clinically significant abnormalities, aside from chronic HBV infection in medical history (e.g., moderate-severe liver disease other than chronic HBV, acute coronary syndrome within 6 months of screening, major surgery within 3 months of screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis coagulopathy) or clinically significant physical examination findings.
- Coinfection with Hepatitis C (cured <12 months at the time of screening), Human immunodeficiency virus or hepatitis D virus
- History of or suspected liver cirrhosis and/or evidence of cirrhosis.
- Diagnosed or suspected hepatocellular carcinoma.
- History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (example, skin cancer). Participants under evaluation for possible malignancy are not eligible.
- History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause), current or history of an autoimmune condition or history/presence of other diseases that may be associated with vasculitis condition (example, systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
- History of extrahepatic disorders possibly related to HBV immune conditions (example, nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
- History of alcohol or drug abuse/dependence:
- Currently taking, or took within 3 months of screening, any immunosuppressing drugs (example, prednisone), other than a short course of therapy (<=2 weeks) or topical/inhaled steroid use.
- Participants, to whom immunosuppressive treatment (including therapeutic doses of steroids) is contraindicated, should not be considered for enrollment in the study.
- Currently taking, or has taken within 6 months of Screening, any interferon-containing therapy.
- Participants requiring anti-coagulation therapies (example, warfarin, Factor Xa inhibitors) or anti-platelet agents (like clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of Investigational medicinal product (IMP) treatment, by the discretion of the investigator. Occasional use is permitted.
- Prior hepatitis B treatment with bepirovirsen, DAP/TOM, or another oligonucleotide or small interfering RNA (siRNA).
- Prior non-hepatitis B treatment with an oligonucleotide or siRNA within 12 months prior to the first dosing day.
- Fridericia's QT correction formula (QTcF) >=450 millisecond (msec) (if single electrocardiogram [ECG] at screening shows QTcF >=450 msec, a mean of triplicate measurements should be used to confirm that participant meets exclusion criterion).
- History of/sensitivity to bepirovirsen, DAP/TOM or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation
- Participants who do not wish to discontinue taking NA therapy for their chronic HBV infection.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment Arm 1A: DAP/TOM + Bepirovirsen
Participants with high Hepatitis B surface antigen (HBsAg) level will receive dose level 1 of DAP/TOM in Treatment Stage 1. After DAP/TOM Treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment. |
Daplusiran/Tomligisiran dose level 1 will be administered Bepirovirsen will be administered |
|
Experimenteel: Treatment Arm 1B: DAP/TOM + Bepirovirsen
Participants with high HBsAg level will receive dose level 2 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment. |
Bepirovirsen will be administered Daplusiran/Tomligisiran dose level 2 will be administered |
|
Experimenteel: Treatment Arm 2A: DAP/TOM + Bepirovirsen
Participants with low HBsAg level will receive dose level 1 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment. |
Daplusiran/Tomligisiran dose level 1 will be administered Bepirovirsen will be administered |
|
Experimenteel: Treatment Arm 2B: DAP/TOM + Bepirovirsen
Participants with low HBsAg level will receive dose level 2 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment. |
Bepirovirsen will be administered Daplusiran/Tomligisiran dose level 2 will be administered |
|
Experimenteel: Treatment Arm 2C: Placebo + Bepirovirsen
Participants with low HBsAg level will receive Placebo in Treatment Stage 1. After Placebo treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment. |
Placebo will be administered Bepirovirsen will be administered |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants achieving functional cure
Tijdsspanne: Up to 100 Weeks
|
The functional cure for HBV is defined as sustained suppression (24 weeks or longer) of HBV deoxyribonucleic acid (DNA) <lower limit of quantification (LLOQ) and HBsAg not detected with or without HBsAb after a finite duration of therapy and off all HBV treatment. The number of participants achieving functional cure after discontinuation of all chronic HBV treatments (DAP/TOM, bepirovirsen, and NA treatment) will be reported. |
Up to 100 Weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants achieving functional cure with high Baseline HBsAg level
Tijdsspanne: Up to 100 Weeks
|
The functional cure for HBV is defined as sustained suppression (24 weeks or longer) of HBV DNA <LLOQ and HBsAg not detected with or without HBsAb after a finite duration of therapy and off all HBV treatment. The number of participants achieving functional cure with high Baseline HBsAg level after discontinuation of all chronic HBV treatments (DAP/TOM, bepirovirsen, and NA treatment) will be reported. |
Up to 100 Weeks
|
|
Number of participants achieving functional cure with low Baseline HBsAg level
Tijdsspanne: Up to 100 Weeks
|
The functional cure for HBV is defined as sustained suppression (24 weeks or longer) of HBV DNA <LLOQ and HBsAg not detected with or without HBsAb after a finite duration of therapy and off all HBV treatment. The number of participants achieving functional cure with low Baseline HBsAg level after discontinuation of all chronic HBV treatments (DAP/TOM, bepirovirsen, and NA treatment) will be reported. |
Up to 100 Weeks
|
|
Number of participants achieving functional cure with low Baseline HBsAg level compared against placebo + bepirovirsen arm
Tijdsspanne: Up to 100 Weeks
|
The functional cure for HBV is defined as sustained suppression (24 weeks or longer) of HBV DNA <LLOQ and HBsAg not detected with or without HBsAb after a finite duration of therapy and off all HBV treatment. The number of participants achieving functional cure with low Baseline HBsAg level after discontinuation of all chronic HBV treatments (DAP/TOM, bepirovirsen, and NA treatment) compared against placebo + bepirovirsen arm will be reported. |
Up to 100 Weeks
|
|
Number of participants with undetected HBsAg and HBV DNA <LLOQ
Tijdsspanne: Up to 48 Weeks
|
The number of participants with undetected HBsAg and HBV DNA <LLOQ at the end of bepirovirsen treatment will be reported. |
Up to 48 Weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: GSK Clinical Trials, GlaxoSmithKline
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Door bloed overgedragen infecties
- Pathologische processen
- Chronische ziekte
- Ziekte attributen
- Infecties
- Virusziekten
- Ziekten van het spijsverteringsstelsel
- Lever Ziekten
- Hepatitis, viraal, menselijk
- Overdraagbare ziekten
- DNA-virusinfecties
- Hepadnaviridae-infecties
- Hepatitis, chronisch
- Hepatitis
- Pathologische aandoeningen, tekenen en symptomen
- Hepatitis B
- Hepatitis B, chronisch
Andere studie-ID-nummers
- 218309
- 2024-514507-33-00 (Ctis)
- 2024-514507-33-00 (Register-ID: CTIS (EU))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD-tijdsbestek voor delen
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD-toegangscriteria voor delen
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .